2.930USDMkt Cap: 569.81M USDP/E: —Last update: 2026-05-21
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap569.81M USD
Enterprise Value274.12M USD
Revenue (TTM)36.00K USD
Gross Profit-66.05M USD
Net Income (TTM)-88.09M USD
Revenue/Share0.0000 USD
Last Price2.930 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS02155H2004
Valuation
P/E (Trailing)—
P/E (Forward)-3.25
PEG32.62
EV/EBITDA-2.85
EV/Revenue7614.34
P/S15828.03
P/B1.34
EPS (TTM)-0.92
EPS (Forward)-0.90
52W Range
2.770100% of range2.930
52W High2.930 USD
52W Low2.770 USD
Profitability
Gross Margin0.00%
Oper. Margin-267247.22%
EBITDA Margin0.00%
Profit Margin-214860.98%
ROE-39.17%
ROA-31.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-67.53M USD
CapEx (TTM)11.00K USD
FCF Margin-118061.11%
FCF Yield-7.46%
Net Debt-295.69M USD
Net Debt/EBITDA3.08
Balance Sheet
Debt/Equity0.16
Current Ratio29.56
Quick Ratio29.43
Book Value/Sh2.181 USD
Cash/Share1.705 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJan 20, 2017
Pay DateSep 14, 2018
Splits
Last Split1:30
Split DateSep 14, 2018
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)16.06 USD
Target Range2.500 USD – 28.00 USD
# Analysts9
Ownership
Shares Out.194.47M
Float164.20M
Insiders0.40%
Institutions55.21%
Short Interest
Short Ratio7.6d
Short % Float18.26%
Short % Out.18.24%
Shares Short35.45M
Short (prev mo.)29.25M
Technical
SMA 503.164 (-7.4%)
SMA 2003.965 (-26.1%)
Beta0.17
S&P 52W Chg28.31%
Avg Vol (30d)3.02M
Avg Vol (10d)2.77M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—